Skip to main content

CC Chemokine Receptor Small Molecule Antagonists in the Treatment of Rheumatoid Arthritis and Other Diseases: A Current View

Buy Article:

$63.00 plus tax (Refund Policy)

CC chemokines and their receptors play a key role in mediating both physiological and pathological processes. Chemokine receptors have been widely recognized as attractive drug targets by the pharmaceutical industry. A number of small molecule chemokine receptor antagonists have been developed for different disease indications, including rheumatoid arthritis (RA). This article describes the pharmacological evidence to support the therapeutic potential of targeting chemokine receptors, and highlights some of the recent progress in the field of developing small molecule antagonists for CC chemokine receptors aiming for RA and other disease applications. Furthermore, with the unsatisfactory clinical success so far, potential solutions leading to better success rates are also discussed.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: CC chemokines; CCR1; CCR2; CCR5; CCR6; Rheumatoid arthritis; Small molecule antagonist

Document Type: Research Article

Affiliations: Merck Research Laboratory, 126 East Lincoln Avenue, Rahway, NJ 07065.

Publication date: 01 September 2010

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more